This filing confirms Sanofi as a cornerstone investor in Latigo's IPO, providing strong validation and potential for future collaboration. Traders should watch for the IPO pricing and any subsequent Sanofi-Latigo partnership announcements, which could drive further upside.
Price Chart
Executive Summary
Sanofi filed a Form 3 initial statement of beneficial ownership for Latigo Biotherapeutics (LTGO), disclosing a significant pre-IPO stake. Sanofi holds 494,800 shares of common stock (post-conversion of Series B Preferred) and a convertible promissory note that will convert into 177,978 additional common shares at the IPO price. This signals a major strategic investment by a large pharma in a pre-revenue biotech, which is a strong endorsement of Latigo's pipeline and technology.
Key Facts
- Sanofi filed a Form 3, disclosing beneficial ownership of 494,800 shares of Latigo Biotherapeutics common stock.
- Sanofi also holds a convertible promissory note that will convert into 177,978 additional common shares at the IPO price.
- The Series B Preferred Stock held by Sanofi converts to common stock on a one-for-one basis automatically upon the IPO closing.
- The convertible promissory note matures on June 17, 2027, but converts automatically at the IPO.
- Sanofi is the beneficial owner through wholly-owned subsidiaries.
Financial Impact
Sanofi's total stake post-IPO conversion will be 672,778 shares (494,800 + 177,978), representing a substantial ownership position in a $1.1B market cap company. The exact dollar value depends on the IPO price, which is undisclosed.
Risk Factors
- The IPO price and conversion terms are not yet disclosed, creating uncertainty about the exact value of Sanofi's stake.
- As a pre-revenue biotech, Latigo's stock is highly dependent on clinical trial outcomes and regulatory approvals, which carry inherent risk.
- Sanofi's large stake could create overhang if they decide to sell shares post-IPO, though lock-up agreements are typical.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-345811 |
| Document: 0001193125-26-345811-index.html | 0001193125-26-345811 |
| Document: 0001193125-26-345811.txt | 0001193125-26-345811 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $23.04 $23.73 | ▲ +2.99% | ▲ +3.54% | $15.10 (−34.44%) |
Aug 12, 2026 10w ago | 3 | $19.38 $20.06 | ▲ +3.54% | ▲ +2.84% | $15.10 (−22.04%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.10 (−18.44%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.10 (−18.44%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.10 (−18.44%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.10 (−18.44%) |
Aug 10, 2026 11w ago | 8-K | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.10 (−18.44%) |
Aug 7, 2026 11w ago | EFFECT | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.10 (−17.23%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.10 (−17.23%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.10 (−17.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers